Tapentadol

3-(3-Dimethylamino-1-ethyl-2-methylpropyl)phenol

Nucynta, Palexia, Yantil, Palexia SR, Nucynta ER

Psychoactive Class

Chemical Class

Tapentadol is a centrally-acting synthetic opioid analgesic of the phenylpropylaminopentane class. First approved by the FDA in 2008,¹ it possesses a dual mechanism of action as both a mu-opioid receptor agonist and norepinephrine reuptake inhibitor.¹² Its analgesic potency falls roughly between tramadol and morphine. Tapentadol carries a high addiction potential and significant risk of respiratory depression in overdose;¹ combining it with other depressants or stimulants is strongly discouraged.

Dosage & Duration

Dosage

Threshold~25 mg

Light25-50 mg

Moderate50-75 mg

Strong75-150 mg

Heavy150+ mg

Bioavailability

~32%

Insufflated administration is ineffective.

Duration

Onset32-32 minutes

After Effects1-12 hours

Total4-6 hours

Half-life

~4 hours

Subjective Effects

The experience is dominated by the classic opioid profile of pain relief, physical relaxation, and mood elevation, with little in the way of sensory alteration. Euphoria and a general lift in mood accompany the analgesia, while the body settles into a relaxed, sedated state. Compared to purely sedating opioids, the headspace tends to remain relatively functional at therapeutic doses, though somnolence becomes prominent as the dose increases.

Physical

Physical relaxation and analgesia define the body experience, alongside typical opioid side effects such as itchiness, dry mouth, constipation, and constricted pupils. Respiratory depression is a dose-dependent risk that becomes dangerous at high doses.

Sedation

Muscle relaxation

Uncomfortable

Itchiness Dry mouth

Cognitive

The mental state is characterized by euphoria and an elevated, contented mood. At higher doses this gives way to increasing drowsiness and mental clouding, progressing toward stupor in overdose.

Emotional

Mood enhancement

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

Tapentadol acts through a dual mechanism as a full agonist at the μ-opioid receptor (MOR) and as a norepinephrine reuptake inhibitor.³ It demonstrates high selectivity for MOR, with at least ten-fold greater affinity compared to δ- and κ-opioid receptors.⁴ In receptor binding studies, tapentadol has a Ki of 60 nM at human MOR and a Ki of 480 nM for norepinephrine reuptake inhibition, with agonist activity comparable to morphine despite approximately one-third the binding affinity.³ Tapentadol also weakly inhibits serotonin reuptake, though this action does not appear to contribute to its analgesic effect.⁴

Pharmacokinetics

Tapentadol has a mean oral bioavailability of approximately 32% due to extensive first-pass metabolism.⁵ It is predominantly metabolized through Phase II conjugation pathways, primarily glucuronidation, with the O-glucuronide representing the major metabolite (approximately 55% of urinary excretion) and a sulfate conjugate accounting for roughly 15%.⁵ Phase I oxidative metabolism plays a minor role: CYP2C9 and CYP2C19 mediate demethylation to N-desmethyl tapentadol (about 13% of the dose), while CYP2D6 mediates hydroxylation to hydroxy tapentadol (about 2%).⁵ None of tapentadol's metabolites are pharmacologically active.⁵ The terminal elimination half-life is approximately four hours after oral administration, with tapentadol and its metabolites almost entirely excreted through the kidneys.⁵

Interactions

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

1,2-BenzodiazepineAcenocoumarolAcetazolamideAcetophenazineAclidinium

TripSit

Tolerance

Full Tolerance

Tolerance to the analgesic and euphoric effects develops with repeated use, as is characteristic of μ-opioid receptor agonists. The rate of tolerance development varies between individuals and is influenced by dosing frequency and duration of use.

Cross Tolerance

Opioids (morphine, oxycodone, hydromorphone, fentanyl, and other μ-opioid receptor agonists)

Harm Potential

Addiction & Dependence

Psychological

High

Tapentadol has high abuse potential comparable to other strong μ-opioid receptor agonists such as morphine, oxycodone, and hydromorphone.⁵ It is commonly abused, misused, and diverted; human abuse liability studies found 50 mg of tapentadol produces opioid effects comparable to 4 mg of hydromorphone. Its water solubility enables abuse via snorting, inhaling, or injection, which significantly increases risk of dangerous consequences.⁶

Physical

High

Physical dependence develops with regular use, and withdrawal symptoms may be more intense and prolonged compared to typical opioids such as codeine or oxycodone due to tapentadol's dual mechanism as both an opioid agonist and norepinephrine reuptake inhibitor. Withdrawal symptoms include anxiety, restlessness, fever, chills, joint pain, nausea, vomiting, stomach cramps, sweating, tremor, and insomnia.⁵ Gradual tapering is recommended rather than abrupt cessation.⁶

Toxicity

Respiratory

Respiratory depression is the primary life-threatening toxicity and occurs through direct suppression of brainstem respiratory centers; this effect is dose-dependent and represents the main cause of death in overdose.⁵

Cardiovascular

Hypotension and bradycardia may occur, particularly at higher doses or in overdose situations; these effects are generally manageable with supportive care.⁶

Gastrointestinal

Reduced gastrointestinal motility commonly results in constipation, nausea, and vomiting during therapeutic use; studies indicate tapentadol causes less constipation and nausea compared with oxycodone.⁷

Seizure Risk

Tapentadol has been demonstrated to reduce the seizure threshold and is contraindicated in people with epilepsy or who are otherwise prone to seizures. Risk is elevated in patients with head trauma, metabolic disorders, or those undergoing alcohol and drug withdrawal.

History & Culture

Discovery and Development

Tapentadol was developed by the German pharmaceutical company Grünenthal during the late 1980s.⁸ The research team, led by chemist Helmut Buschmann, used tramadol as their starting point—a compound the same company had created in…

Legality

By Country

United StatesFDA-approved controlled substance (Narcotic)

Approved by the FDA on November 20, 2008,¹⁸ with the extended-release formulation receiving approval on August 26, 2011.¹¹ Classified as a narcotic analgesic with recognized high potential for misuse and abuse.¹⁹⁹ Due to addiction risks, tapentadol is reserved for patients for whom alternative treatment options are inadequate or unavailable.¹⁹

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Tapentadol article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Tapentadol

3-(3-Dimethylamino-1-ethyl-2-methylpropyl)phenol

Nucynta, Palexia, Yantil, Palexia SR, Nucynta ER

Psychoactive Class

Opioid Depressant

Chemical Class

Phenylpropylaminopentane